Evidence map›Paper›PMID 31444607›Full record

ArticleCancer immunology, immunotherapy : CII2019

Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer.

Mohamed Badr, Korinna Jöhrens, Michael Allgäuer, Melanie Boxberg, Wilko Weichert, Ingeborg Tinhofer, Carsten Denkert, Peter Schirmacher, Albrecht Stenzinger, Jan Budczies

Open access · greenAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Integrated Analysis RevealsFrontiers in oncology · 2020
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Mohamed BadrInstitute of Pathology, Charité Hospital, Berlin, Germany.
Korinna JöhrensInstitute of Pathology, Charité Hospital, Berlin, Germany.
Michael AllgäuerInstitute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
Melanie BoxbergInstitute of Pathology, Technical University of Munich, Munich, Germany.
Wilko WeichertInstitute of Pathology, Technical University of Munich, Munich, Germany.
Ingeborg TinhoferDepartment of Radiooncology and Radiotherapy, Charité Hospital, Berlin, Germany.
Carsten DenkertInstitute of Pathology, Charité Hospital, Berlin, Germany.
Peter SchirmacherInstitute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
Albrecht StenzingerInstitute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
Jan BudcziesInstitute of Pathology, Charité Hospital, Berlin, Germany. jan.budczies@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0002-6668-5327
German Cancer Research Center · DECharité - Universitätsmedizin Berlin · DEHeidelberg University · DEPhilipps University of Marburg · DETechnical University of Munich · DETechnische Universität Dresden · DE

Funding

German Cancer Consortium (DKTK) None
6 · The paper itself

Abstract

Immunotherapy is effective in head and neck squamous cell carcinoma (HNSCC), but only a minority of patients responds to immune checkpoint blockade (ICB). To contribute to a better understanding of the underlying immune biology, we combined histomorphological evaluation and molecular analysis of the HNSCC immune microenvironment in the TCGA cohort. Analyzing digital HE-stained slides, a method for classification of tumor infiltrating lymphocytes (TILs) in the intra-epithelial compartment (ieTILs, present vs. absent) and the stromal compartment (strTILs, high vs. low) was established. We also analyzed the abundance of eight immune cell populations (estimated from RNAseq data) and PD-L1 mRNA expression. Status of ieTILs and status of strTILs were concordant for 61%, but discordant for 39% of tumors. In univariate survival analysis, ieTILs were a positive prognostic marker for DFS in the study cohort (HR = 0.66, p = 0.015) and in the HPV- subcohort (HR = 0.68, p = 0.04), but not in the HPV + subcohort. T cells were a positive prognostic marker for DFS in the study cohort (HR = 0.80, p = 0.03) and in the HPV + subcohort (HR = 0.20, p = 0.001), but not in the HPV- subcohort. In univariate survival analysis, PD-L1 mRNA expression was neither associated with DFS nor with OS. However, in bivariate and multivariate analyses including both PD-L1 mRNA levels and T cells, PD-L1 was a negative prognostic marker of DFS and OS, while T cells remained a positive prognostic marker. In conclusion, ieTILs and strTILs were non-redundant biomarkers in HNSCC and should be evaluated separately. The identified prognostic markers should be evaluated for predictivity in ICB-treated patients.

Indexed as

B7-H1 AntigenBiomarkers, TumorCarcinoma, Squamous CellCohort StudiesEpithelial CellsFemaleHead and Neck NeoplasmsHumansImmunotherapyLymphocytes, Tumor-InfiltratingMaleMiddle AgedPrognosisSequence Analysis, RNAStromal CellsSurvival AnalysisB7-H1 AntigenBiomarkers, TumorHead and neck squamous cell cancer (HNSCC)Immune checkpoint blockadePD-L1T cellsTumor infiltrating lymphocytes (TILs)

Identifiers

PMID31444607
PMCPMC11028183
OpenAlexW2969622421

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.